PL373675A1 - Leczenie wirusowego zapalenia wątroby typu B - Google Patents

Leczenie wirusowego zapalenia wątroby typu B

Info

Publication number
PL373675A1
PL373675A1 PL02373675A PL37367502A PL373675A1 PL 373675 A1 PL373675 A1 PL 373675A1 PL 02373675 A PL02373675 A PL 02373675A PL 37367502 A PL37367502 A PL 37367502A PL 373675 A1 PL373675 A1 PL 373675A1
Authority
PL
Poland
Prior art keywords
hepatitis
virus treatment
virus
treatment
Prior art date
Application number
PL02373675A
Other languages
English (en)
Inventor
Lee Mizzen
Hongwei Liu
Marvin Siegel
Original Assignee
Stressgen Biotechnologies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stressgen Biotechnologies Corporation filed Critical Stressgen Biotechnologies Corporation
Publication of PL373675A1 publication Critical patent/PL373675A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL02373675A 2001-02-05 2002-02-05 Leczenie wirusowego zapalenia wątroby typu B PL373675A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26673301P 2001-02-05 2001-02-05

Publications (1)

Publication Number Publication Date
PL373675A1 true PL373675A1 (pl) 2005-09-05

Family

ID=23015782

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02373675A PL373675A1 (pl) 2001-02-05 2002-02-05 Leczenie wirusowego zapalenia wątroby typu B

Country Status (15)

Country Link
US (2) US6921534B2 (pl)
EP (1) EP1357940A4 (pl)
JP (1) JP2005505238A (pl)
KR (1) KR20030074787A (pl)
CN (1) CN1264572C (pl)
AU (1) AU2002247084B2 (pl)
BR (1) BR0206995A (pl)
CA (1) CA2437503A1 (pl)
IL (2) IL157251A0 (pl)
MX (1) MXPA03006971A (pl)
NZ (1) NZ527664A (pl)
PL (1) PL373675A1 (pl)
RU (1) RU2295536C2 (pl)
WO (1) WO2002062959A2 (pl)
ZA (1) ZA200306040B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
CN100381463C (zh) * 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
GB0303507D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
CN1727362B (zh) * 2004-07-30 2010-12-01 中国人民解放军第二军医大学 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用
JP4736413B2 (ja) * 2004-12-14 2011-07-27 富士ゼロックス株式会社 生体分子保持物及び生体分子の保存方法
EP1835933A4 (en) * 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
WO2006097914A2 (en) * 2005-03-14 2006-09-21 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis
US7622121B2 (en) * 2005-09-21 2009-11-24 New York University Heat shock proteins from Mycobacterium leprae and uses thereof
CN101307310B (zh) * 2007-05-15 2012-08-08 康泰生医科技股份有限公司 具有提高产率及免疫原性的重组蛋白质表达系统
US8088392B2 (en) * 2007-06-18 2012-01-03 Yunxu Cao Capsid proteins and uses therefore
CN101952320B (zh) * 2007-06-18 2013-08-14 上海泽润安珂生物制药有限公司 具有免疫原性的物质
KR101281098B1 (ko) * 2011-06-30 2013-07-02 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도
TWI575070B (zh) * 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2019123252A1 (en) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
US20220305107A1 (en) * 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
CN115976076B (zh) * 2022-07-13 2025-01-28 龙湖现代免疫实验室 HBC-SpyTag003融合基因、其表达载体、单克隆抗体及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666847A (en) * 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
US4797359A (en) * 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
US4547368A (en) * 1983-12-20 1985-10-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitis B core antigen vaccine made by recombinant DNA
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4784941A (en) * 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4906742A (en) 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
EP0345299A1 (en) 1987-02-02 1989-12-13 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis genes encoding protein antigens
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
CA1338778C (en) 1988-06-15 1996-12-10 Richard A. Young Stress proteins and uses therefor
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
EP0478664B1 (en) 1989-06-19 2003-09-17 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
CA2095855C (en) 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
GB9211736D0 (en) 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
CA2164298A1 (en) 1993-06-04 1994-12-22 Richard A. Young Stress proteins and uses therefor
CA2168952A1 (en) * 1993-08-11 1995-02-16 Lynn E. Spitler Prostatic cancer vaccine
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL109790A0 (en) 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
IL123219A0 (en) 1995-08-18 1998-09-24 Sloan Kettering Inst Cancer Method for treatment of cancer and infectious diseases and compositions useful in same
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
ES2258796T3 (es) 1996-11-26 2006-09-01 Stressgen Biotechnologies Corporation Proteinas de fusion que contienen proteinas de estres para inducir respuestas inmunitarias.
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
CA2282426A1 (en) 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
ES2266652T3 (es) 1997-08-05 2007-03-01 Stressgen Biotechnologies Corporation Respuestas inmunologicas contra los antigenos de hpv provocadas por compuestos que contienen un antigeno de hpv y una proteina de stress o un vector de expresion capaz de expresar dichas proteinas.
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
CA2320488C (en) * 1998-02-12 2007-03-06 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
EP1131682A1 (en) * 1998-11-17 2001-09-12 Joo-Sul Kim Programmable time switch
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
WO2001017554A1 (en) 1999-09-10 2001-03-15 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
AU2001227960A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
WO2001053457A2 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
WO2001052877A1 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Compositions and methods to treat neurodegenerative disorders
CZ20024154A3 (cs) 2000-06-26 2003-08-13 Stressgen Biotechnologies Corporation Použití prostředku obsahujícího napojený protein pro výrobu farmaceutického přípravku pro léčení bradavic a chorob a stavů souvisejících s papiloma virem
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用

Also Published As

Publication number Publication date
CN1264572C (zh) 2006-07-19
IL157251A0 (en) 2004-02-19
RU2295536C2 (ru) 2007-03-20
US20020155434A1 (en) 2002-10-24
MXPA03006971A (es) 2004-05-05
US20050152917A1 (en) 2005-07-14
JP2005505238A (ja) 2005-02-24
BR0206995A (pt) 2005-08-16
HK1062579A1 (en) 2004-11-12
EP1357940A4 (en) 2004-03-17
NZ527664A (en) 2006-12-22
WO2002062959A3 (en) 2003-03-06
IL157251A (en) 2009-05-04
WO2002062959A2 (en) 2002-08-15
CN1491116A (zh) 2004-04-21
EP1357940A2 (en) 2003-11-05
ZA200306040B (en) 2004-11-17
KR20030074787A (ko) 2003-09-19
RU2003127021A (ru) 2005-01-20
US6921534B2 (en) 2005-07-26
CA2437503A1 (en) 2002-08-15
AU2002247084B2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
HUP0400882A3 (en) Oncolytic virus therapy
GB2368233B (en) Maintaining virus detection software
GB0112343D0 (en) Well treatment
EP1459776A4 (en) SYRINGE
IL157251A0 (en) Hepatitis b virus treatment
IL153879A0 (en) Modified virus
AU2003206862A8 (en) Hepatitis b vaccines
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
IL143798A0 (en) Hepatitis c virus ns3 protease
EP1437408A4 (en) NOVEL ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST HEPATITIS C VIRUS
AU2003230790A8 (en) Hepatitis c virus sub-genomic replicons
GB0128651D0 (en) Syringe
MXPA03009235A (es) Genes del virus de manchas de anillo de la papaya.
EP1363611A4 (en) RETINOID TREATMENT OF HEPATITIS
GB0103031D0 (en) Novel treatment
SI1436397T1 (sl) Cepivo proti virusu hepatitisa C
GB2377816B (en) Magnetrons
GB0106066D0 (en) Psuedotyped viruses
GB0117198D0 (en) Anti-neoplastic viral agents
GB0130694D0 (en) Treatment
GB0100430D0 (en) Virus strains
GB0100288D0 (en) Virus strains
GB0219619D0 (en) anti-neoplastic viruses
PT1383563T (pt) Métodos para o tratamento do hiv e outros vírus
GB0116837D0 (en) Treatment